AVIR Aviragen Therapeutics Inc.

0.68
-0.04  -6%
Previous Close 0.72
Open 0.74
Price To book 1.42
Market Cap 26281481
Shares 38,649,237
Volume 255,765
Short Ratio 0.75
Av. Daily Volume 186,188

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released February 1, 2017 - primary endpoint not met.
BTA585
Respiratory syncytial virus (RSV)
Phase 2 enrollment to be completed 2H 2017 with data due 1H 2018.
BTA074 5% topical gel
Condyloma
Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)
Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Laninamivir Octanoate - IGLOO
Adults with symptomatic influenza A or B infection